Key Points {#FPar1}
==========

Respimat soft mist inhaler (SMI) was designed to enhance drug delivery to the lungs, reduce the requirements for patient coordination and inspiratory effort, and improve patients' experience and ease of use.With Respimat SMI, lung deposition of drug is high and oropharyngeal deposition is low.Respimat SMI is easy for patients to use correctly and is associated with a high rate of patient preference and adherence and a low rate of discontinuation.

Introduction {#Sec1}
============

The delivery of respiratory medication by inhalation device is critical to the management of pulmonary diseases \[[@CR1], [@CR2]\]. The inhalers used today for the delivery of drugs directly to the lungs are based on a long history of development. Here we briefly describe the development of inhalers and how more recent research has guided inhaler design. We use the Respimat^®^ soft mist inhaler (SMI; Boehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany) as an illustration of how design changes based on the feedback received from patients and healthcare providers have been implemented for real-world use. In addition to the inhaler's technical aspects, we also focus on patient perspectives when using this device, and a comparison of clinical efficacy against a dry powder inhaler (DPI), the Handihaler^®^ (Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany).

Innovative inhalers and aerosol drug discoveries have significantly improved the quality of life (QoL) of patients with pulmonary diseases \[[@CR3]\]. The delivery of therapeutic aerosols began over 3000 years ago, but it was in the 1950s, with the introduction of the metered-dose inhalers (MDIs), that the pharmaceutical aerosol industry was modernized (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR3], [@CR4]\].Fig. 1The development of inhalers (adapted from \[[@CR6]\]). *CFC* chlorofluorocarbon, *DPI* dry powder inhaler, *HFA* hydrofluoroalkane, *pMDI* pressurized metered-dose inhaler

The development of pressurized MDIs in 1956 revolutionized the treatment of lung diseases, providing truly convenient and portable treatment that effectively controlled symptoms of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD) \[[@CR3], [@CR5], [@CR6]\]. Given their ability to deliver drugs to the lungs quickly and effectively, MDIs rapidly became the treatment of choice over earlier nebulizer designs \[[@CR3]\]. Although simple DPIs were available from the mid-19th century, it was not until the late 1960s that breath-actuated DPIs were developed (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR3], [@CR4]\].

Since the 1970s, the use of inhalers for pulmonary drug delivery has become more widespread, and recent research and development into inhaler evolution has focused on optimizing drug delivery to the lungs \[[@CR7]\] through improvements to devices, and also via more sophisticated formulations that disperse easily in the inhaled air-stream \[[@CR8]\].

Correct use of an inhaler is a key contributing factor for effective pulmonary disease management \[[@CR1], [@CR2]\]. Different inhaler types have distinct attributes \[[@CR9], [@CR10]\], some of which can affect patient satisfaction and adherence \[[@CR11], [@CR12]\], thereby impacting clinical outcomes \[[@CR13]\]. Pulmonary disease-management guidelines recommend that inhaled therapy be individualized for each patient, with regular monitoring of inhaler technique \[[@CR1], [@CR2]\], yet the majority of patients with asthma or COPD do not use their inhalers correctly \[[@CR14]\], which can lead to poor disease management, causing increased healthcare costs \[[@CR15]\].

Although MDIs and DPIs are effective and convenient methods for drug delivery and symptom relief, their efficacy is user dependent. For optimal drug delivery using an MDI, the patient needs to coordinate and synchronize actuation and inhalation, while DPIs are dependent on speed of inhalation (specifically, the initial acceleration of the inhalation maneuver), the inhaled volume, and inspiratory effort \[[@CR6], [@CR9], [@CR16]--[@CR18]\]. Patients with cognitive impairment or limited manual dexterity and those with reduced inspiratory flow rate may be unable to effectively use an MDI or DPI \[[@CR19]\]. Therefore, there is a requirement for inhalers that overcome the difficulties patients may have in using MDIs and DPIs. Here we describe the Respimat SMI as an example of how inhalers have evolved in recent years.

Development and Delivery Characteristics of Respimat SMI {#Sec2}
========================================================

The Respimat SMI was developed with the characteristics of an ideal inhaler (Table [1](#Tab1){ref-type="table"}) and the need for a pocket-sized device that can generate a single-breath, inhalable aerosol from a drug solution in mind (Fig. [2](#Fig2){ref-type="fig"}a) \[[@CR20]\].Table 1Characteristics of an ideal inhaler(adapted from \[[@CR6]\])Drug deliveryPatient usePharmaceutical concernsHigh lung depositionSimple to useAbsence of propellantsAerosol generation independent of inspirationPortable and pocket-sizedUniformity of doseProlonged actuation time (\> 1 s)Multi-dose (\> 50 actuations)Resistant to contaminationHigh fine particle dose of aerosolDose counterNo vulnerability to humiditySlow-velocity aerosolFig. 2Schematic drawing of Respimat SMI: **a** schematic, and **b** usability drawings. *SMI* soft mist inhaler.Copyright Boehringer Ingelheim

The main goals of developing the Respimat SMI were to: avoid the use of propellants; reduce the requirements for patient inspiratory effort; enhance drug delivery; and improve patient usability \[[@CR20]\]. Based on user feedback, the Respimat SMI was designed to include several features to improve usability (Fig. [2](#Fig2){ref-type="fig"}b).

To avoid the use of propellants, the effective aspects of nebulizer technology were applied to generate an aerosol inhalant, or "soft mist," from liquid \[[@CR6], [@CR21]\]. Respimat SMI uses an extremely fine nozzle system, the Uniblock, to aerosolize a metered dose of drug solution into tiny particles suitable for inhalation \[[@CR6], [@CR21]--[@CR23]\]. The mechanics of the device are designed to optimize aerosol velocity, particle size, and internal resistance in order to enhance drug delivery into the airways \[[@CR6], [@CR20]\]. Importantly, Respimat SMI actively generates an aerosol independently of the patient's inhalation effort, with a slow velocity and prolonged duration, which facilitates the coordination of actuation and inhalation \[[@CR6], [@CR20]\].

Because the aerosol generated by Respimat SMI has a high fine-particle fraction delivered at a slow velocity, lung deposition is maximized and oropharyngeal deposition minimized, even at low inhalation flows \[[@CR6], [@CR20], [@CR24], [@CR25]\]. More than 60% of the drug dose released by Respimat SMI falls within a fine-particle dose of ≤ 5.0 μm, which enhances drug delivery to the smaller bronchi and bronchioles \[[@CR6]\].

Compared with MDIs and DPIs, Respimat SMI has a favorable lung deposition profile (Fig. [3](#Fig3){ref-type="fig"}) in patients with asthma or COPD, as well as in healthy volunteers \[[@CR26]--[@CR29]\]. Iwanaga et al. \[[@CR26]\] reported that, in six patients with asthma, drug deposition to the whole lung and the peripheral airways using Respimat SMI (57.1% and 39.7%, respectively) was higher than when using MDIs or DPIs (whole lung deposition 20.0--44.3%; peripheral airway deposition 11.3--29.2%; Fig. [4](#Fig4){ref-type="fig"}) by functional respiratory imaging \[[@CR26]\]. The deposition fractions for Respimat SMI in the upper, central, and peripheral airways were in the ranges 41.3--44.3%, 13.8--22.6%, and 34.6--42.4%, respectively \[[@CR26]\].Fig. 3Particle deposition imaging of an inhaled LABA and a LAMA, by inhalation device \[[@CR26]\]. Each inhalation device contains the following bronchodilators: Flutiform, formoterol (LABA); Symbicort, formoterol (LABA); Relvar, vilanterol (LABA); Spiriva Respimat, tiotropium (LAMA). All images were taken from the same subject. *LABA* long-acting β~2~ agonist, *LAMA* long-acting muscarinic antagonist. Reproduced with permission from Iwanaga et al. \[[@CR26]\]Fig. 4Drug deposition fraction of an inhaled LABA and a LAMA, by inhalation device: **a** in the entire lung; **b** in the peripheral airways \[[@CR26]\]. Each inhalation device contains the following bronchodilators: Flutiform, formoterol (LABA); Symbicort, formoterol (LABA); Relvar, vilanterol (LABA); Spiriva Respimat, tiotropium (LAMA). Box shows the upper quartile, median and lower quartile; whiskers show the maximum and minimum values. *BD* bronchodilator, *LABA* long-acting β~2~ agonist, *LAMA* long-acting muscarinic antagonist, *LUNG* whole lung, *PERI* peripheral airway.Adapted with permission from Iwanaga et al. \[[@CR26]\]

DPIs use inhaled air to disaggregate and disperse the powder into the airstream, so each DPI has an inherent level of resistance associated with the dispersal mechanism \[[@CR30]\]. Most DPIs require a high inspiratory flow to overcome the device resistance and achieve effective drug delivery, which can be an issue for some patients, such as the elderly or those with COPD, who may not be capable of generating a sufficient inspiratory flow rate \[[@CR31]\]. Pitcairn and colleagues evaluated the lung deposition of drugs inhaled via the Respimat SMI or an MDI at an average inspiratory flow rate of 30 L/min compared with via a DPI at a target peak inspiratory flow rate of 30 or 60 L/min \[[@CR27]\]. Regardless of whether inhalation through the DPI was fast or slow, the lung deposition profile was worse with the DPI than with either the Respimat SMI or the MDI, with a smaller proportion of the drug reaching the outer lungs and more deposited in the central zones after DPI administration \[[@CR27]\]. In addition, an in vitro mouth--throat deposition model of COPD showed that Respimat SMI delivered a greater modeled dose to the lung (mDTL) than the Breezhaler (59% mDTL with a moderate COPD breathing pattern and 67% mDTL with a very severe COPD breathing pattern with the Respimat SMI vs. 43% and 51%, respectively, for the Breezhaler) \[[@CR32]\].

Part of the reason for the improved deposition in the lungs and reduced oropharyngeal deposition may be the slower aerosol velocity of Respimat SMI relative to other inhalers \[[@CR6], [@CR20]\]. Studies have shown that the aerosol spray velocity of the Respimat SMI (0.84 and 0.72 m/s at 80 and 100 mm from the end of the nozzle, respectively) is lower than that of seven different MDIs; the slowest MDI spray velocity was 2.47 and 1.71 m/s at 80 and 100 mm from the end of nozzle, respectively \[[@CR33]\]. Similarly, the Respimat SMI produces an aerosol cloud that moved much more slowly than aerosol clouds from MDIs (mean velocity 100 mm from the nozzle: Respimat SMI, 0.8 m/s; MDIs, 2.0--8.4 m/s). The soft mist produced by the Respimat SMI had a longer mean duration (1.5 s) than that produced by MDIs (0.15--0.36 s) \[[@CR24]\].

Clinical Equivalence Between Respimat SMI and HandiHaler {#Sec3}
========================================================

Two devices, the HandiHaler DPI and the Respimat SMI, are available for the delivery of long-acting tiotropium maintenance treatment. The HandiHaler (approved in Europe in 2002 and in the USA and Japan in 2004) has been available for longer than the Respimat SMI (Europe 2007; Japan 2010; USA and Canada 2014) \[[@CR34], [@CR35]\], which may explain why it is more commonly prescribed \[[@CR36], [@CR37]\]; however, the use of the Respimat SMI is increasing \[[@CR37]\]. The HandiHaler DPI delivers tiotropium at a licensed dose of 18 μg once daily (QD) \[[@CR34], [@CR38]\], whereas the efficiency of drug delivery with Respimat SMI has meant that a lower dose of tiotropium 5 µg QD is required with Respimat SMI. Despite the differences in dose between the two inhalers, direct comparative studies suggest that the efficacy, pharmacokinetics, and safety of tiotropium delivered at a dose of 5 μg QD by Respimat SMI is comparable with that of tiotropium 18 µg QD delivered by the HandiHaler \[[@CR38]--[@CR40]\].

In a pooled analysis of two 30-week, double-blind, double-dummy, crossover studies in patients with COPD (*N* = 207), lung function improvement \[as measured by forced expiratory volume in 1 s (FEV~1~)\] with tiotropium 5 μg QD delivered by Respimat SMI was noninferior to tiotropium 18 μg QD delivered by HandiHaler (mean trough FEV~1~ response vs. HandiHaler: 0.029 L; *p* \< 0.0001) \[[@CR39]\].

The efficacy and safety of tiotropium 5 µg QD Respimat SMI versus tiotropium 18 μg QD HandiHaler were also investigated in a 4-week, randomized, double-blind, double-dummy, two-way crossover study in Japanese COPD patients (*N* = 157). Lung function improvements demonstrated treatment with tiotropium via Respimat SMI was noninferior to HandiHaler (mean trough FEV~1~ response vs. HandiHaler: 0.008 L; *p* \< 0.001). The incidence of adverse events was similar with Respimat SMI (31%) and HandiHaler (28%) \[[@CR38]\].

A randomized, double-blind, parallel-group study in patients with COPD (TIOSPIR trial; *N* = 17,135) also evaluated the safety and efficacy of tiotropium via Respimat SMI 5 μg QD compared with tiotropium HandiHaler 18 μg QD. Respimat SMI was noninferior to HandiHaler with respect to the risk of death (hazard ratio (HR) 0.96; 95% confidence interval \[CI\] 0.84--1.09) and comparable with HandiHaler with respect to the risk of first exacerbation (HR 0.98; 95% CI 0.93--1.03). Treatment with tiotropium using Respimat SMI had a safety profile and exacerbation efficacy similar to those with tiotropium using HandiHaler \[[@CR40]\].

Patient Perspectives {#Sec4}
====================

Regardless of the technical advantages a device may confer, if patients do not find the inhaler intuitive and easy to use, then adherence may be reduced and poorer symptom control is likely to occur \[[@CR11], [@CR13]\]. Key factors determining inhaler choice that have been identified by European respiratory experts are the ability of the patient to handle the inhaler, the patient's experience with the inhaler, the patient's ability to coordinate their actions, their ability to learn to use the device correctly, and the cost of the device \[[@CR41]\].

As described earlier, the Respimat SMI was designed not only to enhance drug delivery without the use of propellants, but also to allow reliable drug delivery via a device that was easy for patients to use. For example, the internal mechanism of Respimat SMI propels the medication into the lungs without patients having to generate high inspiratory flow, as is required for some DPIs. The slow velocity of the aerosol generated by the Respimat SMI and the longer spray duration relative to MDIs provides the patient with more "time to breathe," so that they do not need to coordinate inhaler actuation and inhalation as closely, or generate as much inspiratory effort, to achieve effective drug deposition \[[@CR24]\].

Ease of Use {#Sec5}
-----------

A survey of 503 patients with COPD asked patients to rank the attributes of an inhaler that are most important to them, and patients consistently rated performance characteristics of the inhaler ahead of convenience characteristics on the Patient Satisfaction and Preference Questionnaire (PASAPQ) \[[@CR42]\]. In fact, the three most important inhaler attributes were all performance characteristics: "Feeling that your medicine gets into your lungs," "Inhaler works reliably," and "Inhaler makes inhaling your medicine easy." This survey found that the Respimat SMI scored highly in both performance and convenience domain scores on the PASAPQ questionnaire (median 81.0 for performance and 83.0 for convenience) \[[@CR42]\]. A number of other studies in patients with COPD or asthma have similarly reported that the Respimat SMI was easy for patients to use and inhale a dose, and that the inhaled dose was felt by patients to be going to the lungs \[[@CR43], [@CR44]\].

Ease of use is particularly important for patients with COPD, many of whom are elderly and have manual dexterity issues, cognitive impairment, or co-morbidities \[[@CR45]\]. As described earlier, many patients with COPD have difficulty obtaining the required inspiratory flow rate to achieve effective drug delivery with DPIs, and peak inspiratory flow rate decreases with age and worsening disease severity \[[@CR31]\]. Older age has also been shown to be associated with worsening inhaler technique \[[@CR46]\]. In this respect, the Respimat SMI has many features that are useful for older patients, including the simplicity of preparing a dose, the ability to obtain drug delivery at low inspiratory flow rates, and the fact that minimal manual dexterity is required to initiate administration \[[@CR41], [@CR45]\]. Possible disadvantages of the Respimat SMI are that the device needs some basic assembly and priming before the first use \[[@CR6]\], and tends to cost more than older inhalers, which can be a consideration for some patients \[[@CR43]\].

Similarly, ease of use is also particularly important in young children; it is common for children to use inhalers incorrectly and this can result in reduced or negligible benefit \[[@CR47]\]. Children may also find it difficult to produce adequate airflow to correctly operate some inhalers \[[@CR47]\]. In a study in children (aged \< 5 years) with respiratory disease, 83% of 4-year-olds achieved adequate inhalation using Respimat SMI unaided or with parental help, and 100% of 3- to 4-year-olds achieved adequate inhalation with the addition of a valved holding chamber \[[@CR47]\].

Several other studies show that the Respimat SMI is easy for patients to use and that patients with asthma or COPD master the correct inhaler technique rapidly after training \[[@CR48], [@CR49]\]. This may be particularly important for older patients who have more difficulty learning the correct technique for using a new inhaler \[[@CR46]\]. Dal Negro and Povero compared the ease and speed with which patients learned to use Respimat SMI compared with the Genuair MDI and the Breezhaler DPI \[[@CR48], [@CR49]\]. Patients mastered the correct inhaler technique for Genuair and Respimat SMI significantly more quickly than for Breezhaler. Moreover, the rapid acquisition of the correct inhaler technique was estimated to save time and money associated with nurse training time \[[@CR49]\].

Given that it is easy to use, it is expected that the Respimat SMI will become at least as popular as the MDIs and DPIs; however, as mentioned above, the Respimat SMI has been on the market for a relatively short period of time \[[@CR34]\] compared with the other devices.

Adherence {#Sec6}
---------

Inhaler characteristics may affect patient adherence \[[@CR50]\], but it is almost impossible to study the impact of the device independently from the effect of the inhaled drug \[[@CR51]\]. In one comparative analysis of adherence with seven different types of inhalers, Respimat SMI was associated with the lowest risk of underuse (5.5%), defined as taking \< 50% of doses as prescribed, in patients with COPD \[[@CR51]\]. MDIs were associated with a higher rate of overuse (taking \> 125% of doses) and a lower rate of optimal use (≥ 75% and ≤ 125%) compared with Respimat SMI in this analysis \[[@CR51]\].

Inadvertent non-adherence may be an important consideration here because patients who use their inhaler incorrectly are not receiving the optimal dose. MDIs have a high rate of errors because of the need to coordinate actuation and inhalation \[[@CR52]\]. In addition, patients using MDIs may still think the inhaler is working when it is empty, which leads to inadvertent underdosing, but this is not possible with the Respimat SMI, which cannot release a dose from an empty device. Alternatively, patients using a Turbuhaler are often unaware of the drug being administered because there is no taste, and may administer a second one "just in case," leading to overdosage.

Patient Preference {#Sec7}
------------------

The practical benefits of the Respimat SMI have been borne out in several clinical studies assessing inhaler preference in patients with obstructive lung disease \[[@CR53]\]. In one such study, the patients who expressed a preference for one inhaler over another (*N* = 201) significantly (*p* \< 0.001) favored the Respimat SMI, with 81% reporting a preference for Respimat SMI compared with 19% favoring the MDI. The total score from the questionnaire was also significantly (*p* \< 0.001) higher for Respimat SMI than for MDI, as were the mean scores for 13/15 satisfaction questions (*p* \< 0.05) \[[@CR53]\].

In another study, 153 patients with asthma were asked to complete a questionnaire to assess patient preferences of Respimat SMI versus DPI. The total satisfaction score was significantly (*p* \< 0.0001) higher for Respimat SMI (85.5) than for DPI (76.9), and the majority of patients preferred Respimat SMI (74%) to DPI (17%). Additionally, the mean willingness-to-continue score for Respimat SMI (80/100) was higher than that for DPI (62/100) \[[@CR44]\].

In a survey conducted in 57 patients with COPD to investigate the preferences for the HandiHaler and Respimat SMI, 46% of patients preferred the Respimat SMI and 18% preferred the HandiHaler \[[@CR35]\]. In a follow-up survey conducted 2--3 years later (*N* = 39), the percentage of patients who preferred the Respimat SMI increased from 39 to 80% \[[@CR35]\]. Similarly, in a randomized comparison in patients with COPD, performance domain scores and total scores in the PASAPQ were significantly higher in the group of patients who were using the Respimat SMI than in the group receiving the same combination of treatments via an MDI (*p* \< 0.001), and patients in the Respimat SMI group were less likely to discontinue treatment (15.3%) compared with the MDI group (23.4%) \[[@CR54]\].

The preference for Respimat in these studies is consistent with other data showing that patients with COPD prefer more modern inhalers to the Handihaler. For example, in trials comparing the low-resistance Breezhaler DPI with the high-resistance HandiHaler DPI, the Breezhaler was superior in both dose delivery and patient preference \[[@CR55], [@CR56]\]. However, comparisons between the Breezhaler and Respimat SMI are not as clear-cut. While there are some data to suggest that patients with COPD prefer the Breezhaler inhaler over Respimat SMI \[[@CR57]\], other studies have found that both devices are ranked equally high by patients \[[@CR58]\]. Comparative studies show that the rate of handling errors was low and similar with both devices \[[@CR57]\]. The most frequent difficulty patients had with the Breezhaler was inserting the capsule into the device \[[@CR57]\], which requires manual dexterity and fine motor skills \[[@CR45]\].

Conclusions {#Sec8}
===========

Aerosol medication remains the cornerstone of treatment for pulmonary conditions, offering targeted drug delivery to the lungs and rapid relief of symptoms.

Respimat SMI was designed with the features of an ideal inhalation device in mind. It actively delivers an aerosol with a high fine-particle fraction at a slow velocity, which improves overall drug deposition in the lungs with less unwanted oropharyngeal deposition. Furthermore, the slower velocity and longer duration of the aerosol cloud delivered by Respimat SMI simplifies coordination of actuation and inhalation for the patient.

All inhalers have potential disadvantages and for the Respimat -- these include cost and the need for priming. However, the patient-centered design features of Respimat SMI generally outweigh these disadvantages, since preference and satisfaction data show that patients find Respimat SMI easy to use and prefer it to other inhalation devices. Improved patient satisfaction may help to promote long-term adherence and improve clinical outcomes with respiratory maintenance therapy.
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